Zengen, Inc. announces novel approach to reduce organ rejection
Study in Transplantation provides strong support for the development of therapeutics utilizing companys proprietary peptide technology
Zengen, Inc. announced today that its scientists have discovered a novel approach to reduce organ rejection based on the Companys proprietary research with alpha-Melanocyte-Stimulating Hormone (a-MSH). The research shows that treatment with the a-MSH peptide caused a significant increase in allograft (transplanted tissue) survival and a marked decrease in leukocyte (or white blood cell) infiltration, one of the main causes of infection leading to organ rejection. The study entitled, “a-Melanocyte-Stimulating Hormone Protects the Allograft in Experimental Heart Transplantation,” appears in the December 15th issue of Transplantation.
“These results demonstrate that the protection of the transplanted tissue from early injury with a-MSH treatment can postpone rejection,” said James Lipton, Ph.D., chief scientific officer and director of Zengen. “This is an important and encouraging advance in the field of organ transplantation and these data provide strong support for the development of anti-rejection therapies utilizing our proprietary peptide molecules based on the larger a-MSH peptide.”
The preclinical study was designed to determine whether a-MSH treatment protects the allograft and prolongs survival in experimental heart transplantation, in the absence of immunosuppressive therapies. Donor cardiac grafts (Brown Norway) were transplanted into the abdomen of recipient (Lewis) rats. Treatments consisted of intraperitoneal injections of the a-MSH peptide or saline from the time of transplantation until sacrifice or spontaneous rejection.
Results show that median survival time of the peptide-treated organs was significantly prolonged (10 days) as compared to the untreated ones (6 days) (p<0.0001). Histopathologic and gene expression patterns of allografts from treated animals, examined 24 hours after transplantation, revealed substantial benefit over untreated animals and persisted over time. At four days post-transplantation, graft histopathologic appearance was healthier in treated animals. Further, the research revealed that treatment with a-MSH caused a marked inhibition of ET-1 gene expression. ET-1 is the most potent endogenous vasoconstrictor yet identified and contributes to reperfusion injury, transplant rejection and several cardiovascular diseases.
“This is a remarkable increase in duration in non-immunosuppressed transplanted organs, as data from this study and others show that hearts transplanted in these animal models are invariably rejected within six to seven days,” added Dr. Lipton. “The beneficial effects of a-MSH treatment observed in these studies could be even more pronounced in clinical transplantation, particularly with regard to its significant role in ET-1 inhibition. We are excited by these findings, especially as we advance our peptide technology program in organ transplantation.”
About Zengen, Inc.
Incorporated in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengens novel molecules were developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). A naturally occurring molecule, a-MSH modulates inflammatory and immune responses. James Lipton, Ph.D., Zengens chief scientific officer, chairman of the scientific advisory board and director, and his collaborators first demonstrated that a-MSH possesses anti-inflammatory properties and uncovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the a-MSH peptide. These discoveries led to the development of Zengens proprietary peptide molecules, including CZEN 002, a synthetic octapeptide. There is abundant evidence of the anti-inflammatory and anti-infective activity of these novel molecules from both in vivo and in vitro research. Zengen is currently conducting phase I/II clinical trials with CZEN 002 in vaginitis. For more information about Zengen, please visit www.zengen.com.
Zengen, Inc. Forward-Looking Statement Disclaimer
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect managements current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
Media Contact
More Information:
http://www.zengen.com/All latest news from the category: Health and Medicine
This subject area encompasses research and studies in the field of human medicine.
Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.
Newest articles
First-of-its-kind study uses remote sensing to monitor plastic debris in rivers and lakes
Remote sensing creates a cost-effective solution to monitoring plastic pollution. A first-of-its-kind study from researchers at the University of Minnesota Twin Cities shows how remote sensing can help monitor and…
Laser-based artificial neuron mimics nerve cell functions at lightning speed
With a processing speed a billion times faster than nature, chip-based laser neuron could help advance AI tasks such as pattern recognition and sequence prediction. Researchers have developed a laser-based…
Optimising the processing of plastic waste
Just one look in the yellow bin reveals a colourful jumble of different types of plastic. However, the purer and more uniform plastic waste is, the easier it is to…